Pancreatic Enzyme Product Activity Steps Up As NDA Deadline Approaches
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
With the NDA submission deadline for previously unregulated pancreatic enzyme products less than a year away, the exocrine pancreatic insufficiency market is heating up as manufacturers of pig-derived products seek to stay on the market and a non-porcine alternative noses closer to submission